Compare Nerdwallet Inc (NRDS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Smith & Nephew plc — how do they compare? Nerdwallet Inc trades at $9.82 (market cap $625.17M), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 17.8× Nerdwallet Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Smith & Nephew plc for 120 Days on average.
| NRDS | SNN | |
|---|---|---|
Market Cap | $625.17M | $11.10B |
Volume | 1,321,316 | 1,051,703 |
Sector | Media | Health |
52-Week High | $15.93 | $37.17 |
52-Week Low | $7.58 | $26.42 |
Typical Hold Time | 45 Days | 120 Days |
Enterprise Value | $539.47M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $10.03, up 10.4% in the last session, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with improving fundamentals - revenue grew from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent news highlights the company's Financial Resilience Index publications and Q2 2026 results showing 6% revenue growth despite search pressure in some product categories.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key risks include organic search volatility and competitive pressures, but strong cash flow generation and attractive valuation multiples (P/E 10.87, P/S 0.81) support the bullish case for long-term investors.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
